Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Falk Nimmerjahn

Showing results (1-10 of 226) with videos related to

Pageof 23
Sort By:
Immunity|January 18, 2020
Keeping T-he Killers at Bay via FcγRIIbFalk Nimmerjahn
Springer Seminars in Immunopathology|November 23, 2006
Activating and inhibitory FcgammaRs in autoimmune disordersFalk Nimmerjahn
European Journal of Immunology|July 4, 2015
A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndromeFalk Nimmerjahn
Handbook of Experimental Pharmacology|March 22, 2025
Role of Antibody Glycosylation in Health, Disease, and TherapyFalk Nimmerjahn
Seminars in Hematology|June 18, 2016
Immunomodulation of immunothrombocytopeniaFalk Nimmerjahn
Journal of Clinical Immunology|March 10, 2016
Translating Inhibitory Fc Receptor Biology into Novel Therapeutic ApproachesFalk Nimmerjahn
Glycobiology|August 29, 2022
Response to Oswald et al.: ST6Gal1 in plasma is dispensable for IgG sialylationAnja Werner, Falk Nimmerjahn
Nature Cancer|March 30, 2022
Zooming in on dendritic cells for CD40 agonistsJulian Hübner, Falk Nimmerjahn
Immunology Letters|January 31, 2012
Low level of FcγRIII expression on murine natural killer cellsMarkus Biburger, Falk Nimmerjahn
Cancer Cell|January 14, 2015
No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancerAnja Lux, Falk Nimmerjahn
Pageof 23

Showing results (1-10 of 226) with videos related to

Sort By:
Pageof 23
Immunity|January 18, 2020
Keeping T-he Killers at Bay via FcγRIIbFalk Nimmerjahn
Springer Seminars in Immunopathology|November 23, 2006
Activating and inhibitory FcgammaRs in autoimmune disordersFalk Nimmerjahn
European Journal of Immunology|July 4, 2015
A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndromeFalk Nimmerjahn
Handbook of Experimental Pharmacology|March 22, 2025
Role of Antibody Glycosylation in Health, Disease, and TherapyFalk Nimmerjahn
Seminars in Hematology|June 18, 2016
Immunomodulation of immunothrombocytopeniaFalk Nimmerjahn
Journal of Clinical Immunology|March 10, 2016
Translating Inhibitory Fc Receptor Biology into Novel Therapeutic ApproachesFalk Nimmerjahn
Glycobiology|August 29, 2022
Response to Oswald et al.: ST6Gal1 in plasma is dispensable for IgG sialylationAnja Werner, Falk Nimmerjahn
Nature Cancer|March 30, 2022
Zooming in on dendritic cells for CD40 agonistsJulian Hübner, Falk Nimmerjahn
Immunology Letters|January 31, 2012
Low level of FcγRIII expression on murine natural killer cellsMarkus Biburger, Falk Nimmerjahn
Cancer Cell|January 14, 2015
No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancerAnja Lux, Falk Nimmerjahn
Pageof 23